Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions

Hypertension

Volumn 42, Issue 3, 2003, Pages 373-379

  Watson, Anna M D ^a   Lambert, Gavin W ^b   Smith, Kathryn J ^a   May, Clive N ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Adrenocorticotropic hormone; Cardiac output; Glucose; Hemodynamics; Sheep; Urotensin

Indexed keywords

ADRENALIN; CORTICOTROPIN; GLUCOSE; UROTENSIN II;

ADRENALIN BLOOD LEVEL; ADRENALIN RELEASE; ANIMAL EXPERIMENT; ARTERY BLOOD FLOW; ARTICLE; CHRONOTROPISM; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; DRUG ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART MUSCLE DP-DT; HEART OUTPUT; HEART RATE; ILIAC ARTERY; INOTROPISM; KIDNEY BLOOD FLOW; MESENTERY BLOOD FLOW; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SHEEP; TACHYCARDIA;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; CENTRAL VENOUS PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPINEPHRINE; FEMALE; HEART RATE; HUMANS; INFUSION PUMPS; INJECTIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; REGIONAL BLOOD FLOW; SHEEP; TIME FACTORS; UROTENSINS;

EID: 0041331762     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000084633.85427.E6     Document Type: Article

References (33)

1. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, Bern HA. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA. 1980;77:5021-5024.
2. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA. 1998;95:15803-15808.
3. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Douglas SA, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401:282-286.
4. Tal M, Ammar DA, Karpuj M, Krizhanovsky V, Naim M, Thompson DA. A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochem Biophys Res Commun. 1995;209:752-759.
5. Elshourbagy NA, Douglas SA, Shabon U, Harrison S, Duddy G, Sechler JL, Ao Z, Maleeff BE, Naselsky D, Disa J, Aiyar NV. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol. 2002;136:9-22.
6. Gibson A. Complex effects of Gillichthys urotensin II on rat aortic strips. Br J Pharmacol. 1987;91:205-212.
7. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol. 2000;131:1262-1274.
8. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol. 2000;131:441-446.
9. Böhm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol. 2002;135:25-27.
10. Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, Balment RJ, Webb DJ. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res. 2002;53:341-347.
11. Affolter JT, Newby DE, Wilkinson IB, Winter MJ, Balment RJ, Webb DJ. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol. 2002;54:617-621.
12. Richards A, Nicholls M, Lainchbury J, Fisher S, Yandle T. Plasma urotensin II in heart failure. Lancet. 2002;360:545-546.
13. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation. 2002;106:2877-2880.
14. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet. 2002;359:1990-1997.
15. Dschietzig T, Bartsch C, Pregla R, Zurbrugg HR, Armbruster FP, Richter C, Laule M, Romeyke E, Neubert C, Voelter W, Baumann G, Stangl K. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept. 2002;110:33-38.
16. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens. 2001;19:2185-2190.
17. Dun SL, Brailoiu GC, Yang J, Chang JK, Dun NJ. Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat. Neurosci Lett. 2001;305:9-12.
18. Gartlon J, Parker F, Harrison DC, Douglas SA, Ashmeade TE, Riley GJ, Hughes ZA, Taylor SG, Munton RP, Hagan JJ, Hunter JA, Jones DN. Central effects of urotensin-II following ICV administration in rats. Psychopharmacology (Berl). 2001;155:426-433.
19. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, Duckles SP, Civelli O. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol. 1999;1:383-385.
20. Lu Y, Zou C, Huang D, Tang C. Cardiovascular effects of urotensin II in different brain areas. Peptides. 2002;23:1631-1635.
21. Lin Y, Tsuchihashi T, Matsumura K, Abe I, Iida M. Central cardiovascular action of urotensin II in conscious rats. J Hypertens. 2003;21:159-165.
22. Conlon JM, Yano K, Waugh D, Hazon N. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J Exp Zool. 1996;275:226-238.
23. Bednarik JA, May CN. Differential regional hemodynamic effects of corticotropin in conscious sheep. Hypertension. 1994;24:49-55.
24. Dawson NF, Tan YY, Macris M, Otvos L Jr, Summers RJ, Tregear GW, Wade JD. Solid-phase synthesis of ovine Leydig cell insulin-like peptide: a putative ovine relaxin? J Pept Res. 1999;53:542-547.
25. Lambert GW, Jonsdottir IH. Influence of voluntary exercise on hypothalamic norepinephrine. J Appl Physiol. 1998;85:962-966.
26. Clark SD, Nothacker HP, Wang Z, Saito Y, Leslie FM, Civelli O. The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat. Brain Res. 2001;923:120-127.
27. de Matteo R, May CN. Inhibition of prostaglandin and nitric oxide synthesis prevents cortisol-induced renal vasodilatation in sheep. Am J Physiol. 1999;276:R1125-R1131.
28. Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine corcicotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology. 1983;36:165-186.
29. Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol. 2001;132:1625-1629.
30. Gibson A, Wallace P, Bern HA. Cardiovascular effects of urotensin II in anesthetized and pithed rats. Gen Comp Endocrinol. 1986;64:435-439.
31. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med. 2000;10:229-237.
32. Kelsall CJ, Balment RJ. Native urotensins influence cortisol secretion and plasma cortisol concentration in the euryhaline flounder, Platichthys flesus. Gen Comp Endocrinol. 1998;112:210-219.
33. Itoh H, McMaster D, Lederis K. Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur J Pharmacol. 1988;149:61-66.